AcuCort AB (publ) (XSAT:ACUC)

Market Cap	187.09M +18.2%
Revenue (ttm)	6.68M -13.4%
Net Income	-26.19M
EPS	-0.12
Shares Out	234.44M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	292,013
Average Volume	509,632
Open	0.7780
Previous Close	0.7940
Day's Range	0.6300 - 0.8200
52-Week Range	0.4990 - 0.9700
Beta	1.33
RSI	65.97
Earnings Date	Apr 28, 2026

About AcuCort AB

AcuCort AB (publ) operates as a pharmaceutical company. It offers Zeqmelit, an oral film containing the glucocorticoid dexamethasone for the treatment of acute allergic reactions, croup in children, nausea and vomiting associated with chemotherapy, and for the treatment of patients with COVID-19 who experience respiratory difficulties and require oxygen therapy. The company was incorporated in 2006 and is based in Lund, Sweden.

• Industry: Pharmaceutical Preparations
• Founded: 2006
• Employees: 4
• Stock Exchange: Spotlight Stock Market
• Ticker Symbol: ACUC

Financial Performance

In 2025, AcuCort AB's revenue was 6.68 million, a decrease of -13.40% compared to the previous year's 7.72 million. Losses were -26.19 million, 50.5% more than in 2024.